AtriCure, Inc. $ATRC Shares Newly Acquired by Yousif Capital Management LLC

Yousif Capital Management LLC bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,551 shares of the medical device company’s stock, valued at approximately $762,000.

A number of other large investors also recently made changes to their positions in the business. Net Worth Advisory Group acquired a new stake in shares of AtriCure during the third quarter worth $305,000. State of Alaska Department of Revenue increased its holdings in shares of AtriCure by 265.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 10,497 shares of the medical device company’s stock worth $589,000 after buying an additional 7,626 shares during the last quarter. NorthCrest Asset Manangement LLC purchased a new position in shares of AtriCure in the 3rd quarter worth about $298,000. Moody National Bank Trust Division purchased a new position in AtriCure in the third quarter valued at approximately $215,000. Finally, Tidal Investments LLC raised its stake in shares of AtriCure by 46.2% in the 2nd quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock valued at $534,000 after acquiring an additional 6,034 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Insider Activity at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director directly owned 14,015 shares in the company, valued at $538,456.30. This trade represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Karl Dahlquist sold 9,370 shares of AtriCure stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 37,686 shares of company stock valued at $1,898,756 over the last ninety days. Company insiders own 4.00% of the company’s stock.

AtriCure Stock Down 2.2%

AtriCure stock opened at $59.88 on Tuesday. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $63.00. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of 267.04 and a beta of 1.24. The company’s 50-day moving average price is $55.80 and its two-hundred day moving average price is $38.28. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ATRC. BTIG Research upped their target price on shares of AtriCure from $55.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Wednesday, October 21st. UBS Group downgraded AtriCure from a “buy” rating to a “sell” rating in a report on Wednesday, October 21st. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Finally, Piper Sandler raised their price objective on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $55.70.

AtriCure Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.